

Ref: MHL/Sec&Legal/2020-21/124

Date: August 11, 2020

To,
Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

Head Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Scrip Code: 542650

Scrip Symbol: METROPOLIS

Sub: Intimation of Press Release for Q1FY21 results

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that, the Company proposes to make a press release on the following topic

'Metropolis Healthcare Limited- Q1FY21 results'

A copy of the press release to be distributed to the media is enclosed herewith.

This is for your information and records.

Yours Faithfully

For **Metropolis Healthcare Limited**

Poonam Tanwani
Company Secretary & Compliance Officer
Membership No. A19182

Encl: a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis Healthcare Ltd records consolidated revenue of INR 143 crore in Q1 FY 20-21

- Conducted 2.65mn tests from 1.37mn patient visits
- Cost rationalization program initiated in April 2020 to **reduce fixed costs by 9%, semi-variable cost by 12% and variable cost by 21%**.
- Goal for quarter 2 is to scale up NON-COVID tests and subsequent revenues
- In June 2020 we achieved 100% revenues (including Covid-19 testing) compared to June 2019. With improving NON-COVID revenues and cost rationalization measures we have achieved **near normal EBITDA margins of 25.2% for the month of June 2020**

Mumbai, August 11, 2020: Metropolis Healthcare Ltd (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its unaudited consolidated financial results today for the first quarter (Q1FY21).

Quarterly Highlights

Rs. 143 Crs

Revenues

55%

Revenue Share of B2C in
Focus Cities (Non-Covid)

2.65 Mn

No. of Tests

Metropolis has been at the forefront of pandemic since day one and today we have seven COVID Capable Labs, the highest number for any private lab chain in the country. We offer the gamut of COVID tests at all locations for the benefit of patients and hospitals. Additionally, we have scaled up our home visits and digital touchpoints to offer convenience to our patients. While COVID 19 testing is expected to increase, we will continue our efforts to service the needs of all patients by scaling up NON COVID testing in the coming quarter.

Enhanced digital footprints, increased testing and optimizing our systems and processes through a technology transformation will help us bring efficiencies and aid us in the new normal. We will continue to keep safety, quality, and hygiene at the core of our patient service. With a strong balance sheet, improving NON-COVID revenues, increasing doctor consultation and cost control initiatives we remain confident of better revenue and EBITDA performance in quarters to come.

Ameera Shah, Promoter & Managing Director, Metropolis Healthcare Ltd

MEDIA RELEASE

GLOBAL ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

AWARDS AND ACCOLADES

Our MD, Ms. Ameera Shah won the Leader of the Year Award by CNBC-AWAAZ CEO Award

Metropolis won the Most Admired Healthcare Company of the Year and our CEO, Mr. Vijender Singh won the "Best Business Leader of the Year" award at Business Leader of the Year Awards, 2020

Metropolis won the award for Best IT Practices at the Data Center Summit, 2019

Metropolis won the 'Best Logistics Network Optimization' & 'Best use of Technology in Logistics' awards announced at the 5th Asian Supply Chain Thought Leadership Summit & Awards in Mumbai.

Our Chairman, Dr. Sushil Shah, won the 'Lifetime Achievement Award' at the South Asia Pacific Healthcare Summit & Business Awards, 2019 for his immense contribution to the diagnostic industry.

Our MD, Ms. Ameera Shah won the 'Best Woman Entrepreneur of the Year' in Healthcare Sector award at the ASSOCHAM Women Leadership Awards

Metropolis won the Patient Experience team of the Year Award at PEXA Awards 2019 in Delhi

Financial Highlights

In INR Crs	Q1FY21	Q1FY20
Revenue from Operations	142.7	203.0
EBIDTA before CSR & ESOP	13.0	55.6
EBIDTA Margin before CSR & ESOP (%)	9.1%	27.4%
Profit After Tax	2.9	26.9
Profit After Tax (%)	2.0%	13.3%

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 19 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports.

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798 Pvt. Ltd.

Ms. Nadhiya Mali – Corporate Communications

nadhiya.mali@metropolisindia.com +91-8879009517

www.metropolisindia.com

SGA Strategic Growth Advisors

Investor Relations Advisors: Strategic Growth Advisors

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Sagar Shroff shogun.jain@sgapl.net /

sagar.shroff@sgapl.net +91-77383 77756